Literature DB >> 12872992

Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest.

Mohammad Farooq1, Sun Young Hwang, Mi Kyung Park, Jung-Chul Kim, Moon Kyu Kim, Young Kwan Sung.   

Abstract

Glypican-3 (GPC3) encodes a cell-surface heparan-sulfate proteoglycan mutated in type 1 Simpson-Golabi-Behmel syndrome (SGBS1), an X-linked overgrowth syndrome. The phenotype of SGBS1 patients and of GPC3 knockout mice suggests that GPC3 plays a negative role in cell proliferation, and an apoptosis-inducing role in specific tissues. Ectopic expression of GPC3 in some cell lines has supported the idea that GPC3 inhibits cell growth. Here we report that blocking endogenous GPC3 expression with an antisense transcript promotes the growth of Hep G2 and Hep 3B hepatoma cell lines. Moreover, antisense inhibition releases Hep 3B cells from cell cycle arrest. Hence, our data further support the notion that GPC3 is an inhibitor of cell proliferation and demonstrate that it modulates cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872992

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  9 in total

1.  Pattern of apoptosis by NS398, a selective COX-2 inhibitor, in hepatocellular carcinoma cell lines.

Authors:  Mi Kyung Park; Moon Kyu Kim; Jung Chul Kim; Young Kwan Sung
Journal:  Cancer Res Treat       Date:  2005-10-31       Impact factor: 4.679

2.  Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.

Authors:  B Li; H Liu; H W Shang; P Li; N Li; H G Ding
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

3.  Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation.

Authors:  Bowen Liu; Shirish Paranjpe; William C Bowen; Aaron W Bell; Jian-Hua Luo; Yan-Ping Yu; Wendy M Mars; George K Michalopoulos
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

4.  Analysis of cellular changes resulting from forced expression of Dickkopf-1 in hepatocellular carcinoma cells.

Authors:  Mi Hee Kwack; Sun Young Hwang; In Seok Jang; Sang Uk Im; Jin Oh Kim; Moon Kyu Kim; Jung Chul Kim; Young Kwan Sung
Journal:  Cancer Res Treat       Date:  2007-03-31       Impact factor: 4.679

Review 5.  Systemic therapy of hepatocellular carcinoma: current status and future perspectives.

Authors:  Domenico Germano; Bruno Daniele
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

6.  Gene expression profiling of liver cancer stem cells by RNA-sequencing.

Authors:  David W Y Ho; Zhen Fan Yang; Kang Yi; Chi Tat Lam; Michael N P Ng; Wan Ching Yu; Joyce Lau; Timothy Wan; Xiaoqi Wang; Zhixiang Yan; Hang Liu; Yong Zhang; Sheung Tat Fan
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

7.  GPC3 reduces cell proliferation in renal carcinoma cell lines.

Authors:  Marina Curado Valsechi; Ana Beatriz Bortolozo Oliveira; André Luis Giacometti Conceição; Bruna Stuqui; Natalia Maria Candido; Paola Jocelan Scarin Provazzi; Luiza Ferreira de Araújo; Wilson Araújo Silva; Marilia de Freitas Calmon; Paula Rahal
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

8.  Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

Authors:  Masafumi Ikeda; Shinichi Ohkawa; Takuji Okusaka; Shuichi Mitsunaga; Satoshi Kobayashi; Chigusa Morizane; Ikue Suzuki; Shunsuke Yamamoto; Junji Furuse
Journal:  Cancer Sci       Date:  2014-03-25       Impact factor: 6.716

9.  Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Authors:  Ahmed Omar Kaseb; Manal Hassan; Sahin Lacin; Reham Abdel-Wahab; Hesham M Amin; Ahmed Shalaby; Robert A Wolff; James Yao; Asif Rashid; Bharathi Vennapusa; Janine Feng; Toshihiko Ohtomo
Journal:  Oncotarget       Date:  2016-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.